Abstract 485P
Background
Gliomas are primary tumors originating in the brain parenchyma known for their aggressive and diffusive behavior. The diagnosis is based on pathological anatomy that consists of morphological, immunohistochemical and molecular analysis. Simulating the behavior of gliomas in mathematical modeling is a powerful tool in evaluating tumor growth, as well as assisting in therapeutic decision-making.
Methods
We propose a mathematical model of continuous evolution of glioma that seeks to predict its spatio-temporal evolution through interactions of cell populations (concentration (C) of cancer cells “C_C” and dead cells “C_m”) with microenvironment (Mev) nutrients (nutrient C “ C_n”). As it is a complex phenomenon, this model takes into account the process of cell division (proliferation), death and motility. The cell division rate is assumed to follow a logistic model where the proliferation coefficient “r(C_C, C_n)” will be evaluated depending on the C of diseased cells (C_C) and nutrients (oxygen - C_n). The motility coefficient (D_c) and the Mev support capacity (C_Tmax) vary spatially as presented in the literature. For the cell death rate, it was considered that this is a function of the nutrient concentration “k_cm (C_n)” in the Mev. The non-linear system of partial differential equations, for the variables Cc (t,x), Cm (t,x), and Cn (t,x),was solved by the Method of Lines (MOL).
Results
In table we present some results for the average tumor cell population (Nc - Cells) as a function of time (in the limit cases when kn and kcm are very small and a = 0, 62.5) and comparisons with literature data. Nc - Cells for a = 0 and a = 62.5. Table: 485P
t (days) | a = 0 | a = 62.5 | ||||
Present | Ref. [1] | Ref. [2] | Present | Ref. [1] | Ref. [2] | |
1080 | 1710 | — | 1752 | 3116 | 3134 | 3126 |
Conclusions
Results for C, Nc - Cells, average tumor size and growth rate were obtained and compared to those available in the literature, showing that the presente model, with contributions that make it more rigorous and complex, appears to be physically coherent and capable of evaluating the spatio-temporal tumor growth.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16